NeuroBo to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
NeuroBo to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
For more information, please visit .CAMBRIDGE, Mass., Sept. 3, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that Hyung Heon Kim, President and Chief Executive Officer and Marshall H. Woodworth, Chief Financial Officer, will present a company overview on Tuesday, September 10, at 1:30 pm ET, during the H.C. Wainwright 26th Annual Global Investment Conference taking place September 9-11, 2024, in New York.
馬薩諸塞州劍橋，2024年9月3日/美通社/--neurobo pharmaceuticals股份有限公司(納斯達克代碼：NRBO)，一家專注於轉化心臟代謝疾病的臨床生物技術公司，今日宣佈，公司總裁兼首席執行官金賢和，首席財務官馬歇爾·伍德沃思將於2024年9月10日星期二下午1:30在H.C. Wainwright第26屆全球投資大會上作公司概況介紹，該大會將於2024年9月9日至11日在紐約舉行。
Management will also be available for one-on-one meetings during the event. Institutional investors who would like to listen to the Company's presentation or request a meeting can do so after registering for the conference at . To schedule a meeting with management outside of the conference, investors can contact Michael Miller at [email protected].
管理層也會在活動期間提供一對一會議。希望聽取公司介紹或請求會議的機構投資者可以在註冊參加會議後這樣做。要安排與管理層在會議之外的會議，投資者可以通過聯繫邁克爾·米勒（Michael Miller）發郵件至[email protected]。
About NeuroBo Pharmaceuticals
NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity, and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. DA-1241 is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In pre-clinical studies, DA-1241 demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control.
關於NeuroBo Pharmaceuticals
neurobo pharmaceuticals股份有限公司是一家專注於轉化心臟代謝疾病的臨床生物技術公司。該公司目前正在開發DA-1726用於肥胖治療，正在開發DA-1241用於治療代謝功能相關脂肪肝（MASH）。DA-1726是一種新型氧雲調質激素（OXM）類似物，作爲胰高血糖素樣肽-1受體（GLP1R）和胰高血糖素受體（GCGR）雙激動劑發揮作用。OXm是一種天然存在的腸道激素，能激活GLP1R和GCGR，從而減少食物攝入量並增加能量消耗，從而可能導致相對於選擇性GLP1R激動劑更好的體重減輕。DA-1241是一種新型的G蛋白偶聯受體119（GPR119）激動劑，能促進關鍵的腸道肽GLP-1，GIP和PYY的釋放。在臨床前研究中，DA-1241顯示出對肝臟炎症，脂質代謝，體重減輕和葡萄糖代謝具有積極作用，減少肝脂變性，肝炎炎症和肝纖維化，同時改善葡萄糖控制。
For more information, please visit .
有關更多信息，請訪問。
Contacts:
聯繫人：
NeuroBo Pharmaceuticals, Inc.
Marshall H. Woodworth
Chief Financial Officer
+1-857-299-1033
[email protected]
NeuroBo Pharmaceuticals, Inc.
Marshall H. Woodworth
致富金融(臨時代碼)
+1-857-299-1033
[email protected]
Rx Communications Group
Michael Miller
+1-917-633-6086
[email protected]
Rx Communications Group
Michael Miller
+1-917-633-6086
[email protected]
SOURCE NeuroBo Pharmaceuticals, Inc.
來源：NeuroBo Pharmaceuticals，Inc。
譯文內容由第三人軟體翻譯。